GPT Healthcare share price & results

GPT Healthcare Limited· Healthcare

Results to: Jun 2026
Latest analysed call: Q1 FY27
Ownership as of: Sept 2026

Runs five ILS-brand tertiary-care hospitals (719 beds) across West Bengal, Tripura and Chhattisgarh.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	126 ₹ crore	+17.8% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	19.0 %	+3.0 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	13.0 ₹ crore	+62.5% YoY	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed.
Return on equity	Unavailable	+12.7 ptsFY Mar 2022 vs FY Mar 2021	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.
Free cash flow margin	Unavailable	+1.9 ptsFY Mar 2022 vs FY Mar 2021	Fiscal year	FY · period unavailable	Not in the analysed materials. No older figure is substituted.
Revenue growth (YoY)	Unavailable	+24.1 ptsFY Mar 2022 vs FY Mar 2021	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

GPT Healthcare Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (2 achieved, 2 missed, 14 open).

Target	Original wording	Said	Latest call	Verdict
FY26 YoY Revenue Growth	Grow at a 15% Y-o-Y growth Call transcript, Q4 FY25 · 24 May 2025	Q4 FY25	Q1 FY27:Promise concluded in FY26. Final status was 'achieved'. Call transcript, Q1 FY27 · 4 Aug 2026	Achieved
FY26 Consolidated EBITDA Margin	Expect the EBITDA margin to be 22.5% to 23% overall Call transcript, Q4 FY25 · 24 May 2025	Q4 FY25	Q1 FY27:Promise concluded in FY26. Final status was 'missed'. Call transcript, Q1 FY27 · 4 Aug 2026	Missed
Total Bed Capacity	1,000 bed challenge by FY '27 / next 2 to 3 years Call transcript, Q3 FY25 · 12 Feb 2025	Q3 FY25	Q1 FY27:Reiterated target of over 1,000 beds, but timeline pushed to 'next 2 years' (approx. Q1 FY29), a delay from the original 'by FY27' target. Call transcript, Q1 FY27 · 4 Aug 2026	Delayed

Source: Inve Guidance Tracker for GPT Healthcare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of GPT Healthcare Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.

See the full record

Price

₹134.1 +3.21% · +₹4.17

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −9.8% 1Y

1Y: ₹148.62 on 24 Oct 2025 → ₹134.1. High ₹170.49 (31 Jul 2026), low ₹115.31 (30 Mar 2026).

Previous close: ₹129.93
Market cap: ₹1.1k Cr
52-week range: ₹115.31 – ₹170.49
One year: −10.68%

Overview

Symbol: NSE:GPTHEALTH
Sector: Healthcare
Exchange: NSE
Currency: INR

What GPT Healthcare Limited does

Based on the company's own presentations, annual report and earnings calls.

GPT Healthcare operates under the ILS Hospitals brand, running a network of neighborhood tertiary and quaternary-care hospitals located within dense residential catchments in Eastern India for high patient accessibility. It earns from inpatient and outpatient hospital services spanning oncology, interventional cardiology, nephrology (including renal transplants), gastroenterology, orthopaedics and robotic surgery, backed by in-house diagnostics such as MRI, CT and cardiac catheterization labs. The company also runs ancillary digital and home-care offerings, including a senior-citizen home-healthcare programme and a patient-facing mobile app. A sixth hospital, a 150-bed facility in Jamshedpur, is under construction.

Segments

Hospital Services

Hospitals operated: 5
Total bed capacity: 719 beds
Full-time consultants: 115
Visiting consultants: 630
Cumulative robotic surgeries performed: 800+
Quality accreditations: NABH & NABL accredited

Founded 2000Headquarters Kolkata, West Bengal, IndiaEmployees 1,924 (2025-03-31) Company website

How the price took the results

close before → close after

Q1 FY27: −1.1%; 4 Aug
Q4 FY26: +2.9%; 19 May
Q3 FY26: +0.8%; 3 Feb
Q2 FY26: −0.0%; 11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

GPT Healthcare Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (2 achieved, 2 missed, 14 open).

Target	Original wording	Said	Latest call	Verdict
FY26 YoY Revenue Growth	Grow at a 15% Y-o-Y growth Call transcript, Q4 FY25 · 24 May 2025	Q4 FY25	Q1 FY27:Promise concluded in FY26. Final status was 'achieved'. Call transcript, Q1 FY27 · 4 Aug 2026	Achieved
FY26 Consolidated EBITDA Margin	Expect the EBITDA margin to be 22.5% to 23% overall Call transcript, Q4 FY25 · 24 May 2025	Q4 FY25	Q1 FY27:Promise concluded in FY26. Final status was 'missed'. Call transcript, Q1 FY27 · 4 Aug 2026	Missed
Total Bed Capacity	1,000 bed challenge by FY '27 / next 2 to 3 years Call transcript, Q3 FY25 · 12 Feb 2025	Q3 FY25	Q1 FY27:Reiterated target of over 1,000 beds, but timeline pushed to 'next 2 years' (approx. Q1 FY29), a delay from the original 'by FY27' target. Call transcript, Q1 FY27 · 4 Aug 2026	Delayed

Source: Inve Guidance Tracker for GPT Healthcare Limited · to Q1 FY27

The full ledger

Open GPT Healthcare Limited’s full ledger

A free account opens 5 company ledgers a month. All 18 tracked commitments, with each call’s wording and source.

Browse the register

Latest analysed call: Q1 FY27, 4 Aug 2026. 7 calls analysed.

Call summaries

Q1 FY27 — 4 Aug 2026

GPT Healthcare Limited Q1 FY27

GPT Healthcare Limited delivered a strong Q1 FY27, with total income growing 18.2% and PAT surging 66% year-over-year, driven by improved ARPOB and healthy occupancy in mature hospitals. While Agartala faced temporary occupancy dips due to local elections and Raipur continued to incur losses, both are showing signs of recovery and progress. The company remains focused on strategic expansion, clinical excellence, and achieving long-term profitability targets.

Read the full call

Q4 FY26 — 19 May 2026

GPT Healthcare Q4 FY26

GPT Healthcare delivered strong Q4 and FY26 operational performance, marked by significant revenue growth and margin expansion in mature hospitals. The newly commissioned Raipur facility, however, weighed on overall profitability with a negative EBITDA contribution and lower-than-expected occupancy due to delays in insurance empanelment. The company is focused on ramping up Raipur, commissioning Jamshedpur, and evaluating M&A opportunities to achieve its 1,000-bed hospital chain vision.

Read the full call

Q3 FY26 — 3 Feb 2026

GPT Healthcare Q3 FY26

GPT Healthcare delivered a strong 9MFY26 performance with double-digit revenue growth and stable margins, driven by improved occupancy and strategic service expansion across its mature hospitals. The new Raipur facility is progressing well towards breakeven, and the company remains focused on its 1,000-bed expansion target by 2027 through both organic and inorganic growth opportunities in Eastern India.

Read the full call

Summaries of each call, in Inve’s own words; the transcript is not reproduced. Not investment advice.

Every analysed call

GPT Healthcare Limited earnings calls (GPTHEALTH)

Fundamentals

Ratios, each with its period

Current values with the period they cover; the trend reads across the 3 fiscal years held (Mar 2020 to Mar 2022).

Mar 2020 Mar 2021 Mar 2022
30.00 days 26.00 days 15.00 days

How it is calculated. Reported receivable days from the annual accounts.
Mar 2020 Mar 2021 Mar 2022
60.00 days 41.00 days 30.00 days

How it is calculated. Reported inventory days, using material cost / cost of goods sold.
Mar 2020 Mar 2021 Mar 2022
314.00 days 165.00 days 121.00 days

How it is calculated. Reported payable days, using material cost / cost of goods sold.
Mar 2020 Mar 2021 Mar 2022
-224.00 days -98.00 days -76.00 days

How it is calculated. Reported debtor days plus inventory days less payable days.
Mar 2020 Mar 2021 Mar 2022
-4.00 days 32.00 days 3.00 days

How it is calculated. Reported net working capital days from the annual accounts.
Mar 2020 Mar 2021 Mar 2022
0.00% 47.00% 115.00%

How it is calculated. Reported dividend payout as a percentage of annual profit.
Mar 2020 Mar 2021 Mar 2022
— — —

How it is calculated. Market capitalisation from the current stock record.

Mar 2020	Mar 2021	Mar 2022
30.00 days	26.00 days	15.00 days

Mar 2020	Mar 2021	Mar 2022
60.00 days	41.00 days	30.00 days

Mar 2020	Mar 2021	Mar 2022
314.00 days	165.00 days	121.00 days

Mar 2020	Mar 2021	Mar 2022
-224.00 days	-98.00 days	-76.00 days

Mar 2020	Mar 2021	Mar 2022
-4.00 days	32.00 days	3.00 days

Mar 2020	Mar 2021	Mar 2022
0.00%	47.00%	115.00%

Mar 2020	Mar 2021	Mar 2022
—	—	—

A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →

Financials

What the filings say

Net profit, year on year: +63% (quarter to jun 2026 against jun 2025).

In ₹ crore. Oldest period first.

Line item	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	106	102	101	107	119	120	126	126
Expenses	82	81	81	90	96	99	103	102
Operating profit	23	21	21	17	23	21	23	24
Operating margin	22.0%	21.0%	20.0%	16.0%	19.0%	17.0%	18.0%	19.0%
Other income	3	2	2	2	1	1	2	2
Interest	1	1	1	2	2	2	2	2
Depreciation	5	5	5	6	7	7	7	7
Profit before tax	21	18	16	11	15	13	16	17
Tax rate	28.0%	30.0%	21.0%	31.0%	30.0%	27.0%	8.0%	26.0%
Net profit	15	12	13	8	11	9	15	13
EPS (₹ per share)	1.81	1.49	1.57	0.94	1.29	1.14	1.78	1.55

Source: Inve data · income statement, quarterly · to Jun 2026

In ₹ crore. Oldest period first.

Line item	Mar 2024	Mar 2025	Mar 2026
Sales	400	407	472
Expenses	312	324	388
Operating profit	88	83	84
Other income	5	9	6
Interest	8	4	8
Depreciation	17	20	27
Profit before tax	67	70	55
Net profit	48	50	43

Source: Inve data · income statement, annual · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sept 2025	Mar 2026
Equity capital	80	80	82	82	82	82
Reserves	78	85	136	166	172	187
Borrowings	102	82	31	35	97	91
Other liabilities	63	79	96	101	113	104
Total liabilities	323	327	346	384	463	465
Fixed assets	220	228	224	228	342	342
Capital work in progress	1	3	6	46	2	1
Investments	10	13	30	32	32	43
Other assets	92	83	85	78	87	79
Total assets	323	327	346	384	463	465

Source: Inve data · balance sheet · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operations	43	66	66	69	67	81
Cash from investing	-16	-5	5	-25	-33	-47
Cash from financing	-22	-57	-73	-48	-35	-31
Net cash flow	4	3	-2	-5	0	2
Free cash flow	38	59	58	50	18	40

Source: Inve data · cash flow · to Mar 2026

In days and %. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	26	15	21	22	18	16
Inventory days	41	30	43	36	41	43
Days payable	165	121	161	165	161	170
Cash conversion cycle	-98	-76	-97	-106	-102	-112
Working capital days	32	3	-18	-16	-28	-29
Return on capital employed	14.0%	23.0%	25.0%	30.0%	27.0%	20.0%
Dividend payout	47.0%	0.0%	102.0%	60.0%	41.0%	49.0%

Source: Inve data · annual ratios · to Mar 2026

Ownership

Who owns it

Promoters hold 65.57% as of Sept 2026; institutions added 0.14 pts since Jun 2026.

Promoters 0.00 pts 65.57%
Foreign institutions −0.02 pts 3.01%
Domestic institutions +0.16 pts 7.10%
Public −0.14 pts 24.32%

59,151 shareholders on the register.

Source: Exchange shareholding filings · to Sept 2026 · 8 filings held

Who was buying across the market this quarter

Who is on the register

Named in the Sep 2026 filing

Every holder of GPT Healthcare Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.

Holder	Stake	Change
	65.57%	unchanged
Mutual fund	4.61%	unchanged
	2.74%	unchanged
NBFC / DFI	1.20%	unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Your own record

Start an Inve Case for GPT Healthcare Limited

Free account: one company. Everything above stays public.

Write why you follow GPT Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse GPT Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.

Performance −9.8% 1Y

What GPT Healthcare Limited does

How the price took the results

Q1 FY27 — 4 Aug 2026

Q4 FY26 — 19 May 2026

Q3 FY26 — 3 Feb 2026

What the price assumes

Who is on the register

Learn to analyse GPT Healthcare Limited